Aytu Biopharma

Aytu Biopharma is a specialty pharmaceutical company focused on developing and commercializing products for various healthcare conditions. The company primarily targets urological indications, with an emphasis on male sexual dysfunction and male infertility, while exploring opportunities in other related areas. In addition to its urological focus, Aytu Biopharma offers prescription therapeutics for attention deficit hyperactivity disorder and other common pediatric conditions. The company is also advancing a therapeutic pipeline that includes AR101/enzastaurin, a prospective treatment for vascular Ehlers-Danlos Syndrome, a rare genetic disorder characterized by serious health complications. This treatment has received Orphan Drug designation from the FDA, highlighting its potential importance in addressing unmet medical needs. Aytu Biopharma’s diverse portfolio reflects its commitment to improving patient outcomes across various therapeutic areas.

Jarrett Disbrow

Executive Vice President, Corporate Operations

3 past transactions

Neos Therapeutics

Acquisition in 2020
Neos Therapeutics, Inc. is a pharmaceutical company based in Grand Prairie, Texas, focused on the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD). Utilizing its proprietary drug delivery technology platform, Neos produces extended-release medications in various forms, including orally disintegrating tablets and liquid suspensions. Its product lineup features Adzenys XR-ODT and Adzenys ER, both amphetamine-based treatments, and Cotempla XR-ODT, a methylphenidate formulation, all designed to address ADHD symptoms. Additionally, the company markets generic Tussionex, a hydrocodone and chlorpheniramine polistirex oral suspension for cough relief. Neos is also developing NT0502, a clinical-stage candidate aimed at treating chronic sialorrhea associated with certain neurological conditions. The company operates primarily in the United States and is committed to creating high-quality products that meet significant medical needs.

Innovus Pharmaceuticals

Acquisition in 2019
Innovus Pharmaceuticals is a San Diego-based pharmaceutical company founded in 2011 that focuses on developing, in-licensing, acquiring, and marketing both prescription and consumer health products. The company specializes in areas such as dermatology, autoimmune disorders, respiratory diseases, and sexual dysfunction, aiming to enhance patient compliance and outcomes through innovative packaging and presentation. Innovus Pharma is committed to the commercialization and licensing of safe, effective non-prescription medications and consumer care products that address the health and vitality of both men and women. Its distribution strategy includes working with commercial partners to reach primary care physicians, urologists, gynecologists, and therapists, as well as selling products directly to consumers.

Nuelle

Acquisition in 2017
Nuelle is a sexual wellness and intimate care company focused on delivering groundbreaking solutions made specifically for women. It marries its experience in healthcare solutions, consumer products, and technology with a deep understanding of women’s unfulfilled needs. From inception, Nuelle has taken a holistic view of these needs and desires. They worked closely with thought leaders and experts in women’s sexual medicine and wellness including physicians, sex therapists, physical therapists, and psychologists. Together we developed insights that allow Nuelle to translate its scientific approach to understanding.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.